{"id":38489,"date":"2026-04-29T09:35:00","date_gmt":"2026-04-29T13:35:00","guid":{"rendered":"https:\/\/www.drugpatentwatch.com\/blog\/?p=38489"},"modified":"2026-04-27T08:54:54","modified_gmt":"2026-04-27T12:54:54","slug":"patent-term-restoration-vs-adjustment-the-300-billion-clock-pharma-cant-afford-to-misread","status":"publish","type":"post","link":"https:\/\/www.drugpatentwatch.com\/blog\/patent-term-restoration-vs-adjustment-the-300-billion-clock-pharma-cant-afford-to-misread\/","title":{"rendered":"Patent Term Restoration vs. Adjustment: The $300 Billion Clock Pharma Can’t Afford to Misread"},"content":{"rendered":"\n
\"\"<\/figure>\n\n\n\n

Every pharmaceutical patent starts its life with a 20-year timer running from the filing date. By the time a new drug reaches FDA approval, that clock has already consumed seven to twelve years. What remains \u2014 often between eight and thirteen years of enforceable exclusivity \u2014 must carry the entire commercial weight of a development program that cost, on average, $2.6 billion and took more than a decade to execute. Two legal mechanisms exist to reclaim some of what the clock ate: Patent Term Restoration under 35 U.S.C. \u00a7 156 and Patent Term Adjustment under 35 U.S.C. \u00a7 154(b). Both are statutory rights. Neither is automatic. And the difference between capturing them correctly and losing them to procedural error can run into the billions.<\/p>\n\n\n\n

A single additional day of patent exclusivity on Keytruda (pembrolizumab) is worth roughly $8.2 million in gross revenue based on Merck’s 2024 annual sales. That figure is not an abstraction \u2014 it is the operating reality that defines how pharmaceutical IP teams should think about every deadline, every filing sequence, and every prosecution decision throughout the life of a drug patent. When a company misses the 60-day window to apply for Patent Term Extension, or fails to notice a USPTO coding error that understated its Patent Term Adjustment, it is not losing paperwork. It is leaving revenue on the table at a rate that most industries never see in a fiscal year.<\/p>\n\n\n\n

Between 2025 and 2030, the global pharmaceutical industry faces a Loss of Exclusivity wave that puts an estimated $200 billion to $400 billion in branded revenue at risk, with over 190 drugs, including 69 blockbusters, projected to lose exclusivity in that window. Against that backdrop, the tools available to extend legitimate patent protection have never been more commercially consequential \u2014 or more legally contested.<\/p>\n\n\n\n

This guide works through both mechanisms in the technical and strategic depth they require, using real litigation, real drugs, and real calculations to show what the difference looks like in practice.<\/p>\n\n\n\n

\n\n\n\n

The Structural Problem Both Mechanisms Address<\/strong><\/h2>\n\n\n\n

Why the 20-Year Term Was Broken Before Hatch-Waxman<\/strong><\/h3>\n\n\n\n

Before the Hatch-Waxman Act, the patent term would continue to run whether or not the FDA had approved the claimed pharmaceutical for marketing. As a result, the period during which the proprietor of a patent claiming a regulated drug could actually enjoy exclusivity was often quite significantly reduced. In effect, each day of delay associated with the FDA approval process amounted to a lost day of patent term.<\/p>\n\n\n\n

The pre-1984 regime created a structural misalignment. Congress designed the patent system to give inventors a limited monopoly that would allow commercial exploitation and recovery of development costs. For most industries, the delay between filing and commercialization is measured in months, not years. Drug development operates on a different timeline. An IND application typically follows patent filing by two to three years, after which clinical trials consume another six to ten years before an NDA reaches FDA reviewers. By the time FDA approval arrives, a composition-of-matter patent filed in year one of the discovery program may have seven to twelve years of enforceable term remaining. Against a development cost of billions, that window is often inadequate to generate a positive return on investment.<\/p>\n\n\n\n

With the advent of Hatch-Waxman, part of the time spent seeking regulatory approval can be regained by lengthening the patent term of an eligible patent in order to compensate for this type of delay. Under Hatch-Waxman, Patent Term Extension is available to eligible patents covering human drug products, veterinary drug products, and medical devices.<\/p>\n\n\n\n

The 1984 Act created the Patent Term Extension mechanism. The 1999 American Inventors Protection Act added Patent Term Adjustment for a different but related problem: delays caused not by the FDA but by the USPTO itself during patent prosecution.<\/p>\n\n\n\n

\n\n\n\n

Patent Term Restoration Under 35 U.S.C. \u00a7 156: The Full Mechanics<\/strong><\/h2>\n\n\n\n

What Section 156 Actually Says<\/strong><\/h3>\n\n\n\n

The PTE doctrine comes from Title II of the Drug Price Competition and Patent Term Restoration Act of 1984. The purpose of Hatch-Waxman is to encourage new drug research by compensating for reductions in patent term arising from the requirement that certain drug products must first obtain federal regulatory approval before they can be marketed in the United States.<\/p>\n\n\n\n

Section 156 allows a patent owner to apply for an extension of term that compensates for the regulatory review period consumed by the FDA approval process. The extension does not simply tack on the full review period. Congress built in a formula that compensates for a portion of the testing phase and the full approval phase, subject to caps that prevent the extension from becoming a windfall.<\/p>\n\n\n\n

The formula has two components. The testing phase runs from the effective date of the Investigational New Drug application to the date the NDA is filed. The approval phase runs from the NDA filing date to the date FDA grants approval. The total eligible period is the half of the testing phase plus the full approval phase, reduced by any periods when the applicant failed to exercise due diligence in pursuing FDA review.<\/p>\n\n\n\n

The key limitations are that the extension cannot exceed five years, and no patent can exceed 14 years of exclusivity from FDA approval.<\/p>\n\n\n\n

The 14-year cap from approval is the operational ceiling that most practitioners focus on. A drug approved after a long regulatory review period may find that the five-year maximum extension leaves it with more than 14 years of post-approval term, in which case the extension is capped at whatever number produces exactly 14 years from the approval date. For drugs with shorter regulatory review periods \u2014 a Priority Review drug that moved quickly from NDA to approval \u2014 the five-year maximum may be the binding constraint instead.<\/p>\n\n\n\n

Eligibility: The Four Conditions<\/strong><\/h3>\n\n\n\n

Section 156 imposes four conditions, all of which must be satisfied before a PTE application can be granted.<\/p>\n\n\n\n

First, the patent must claim the product subject to regulatory review. This sounds straightforward, but the Federal Circuit has interpreted ‘claims’ narrowly in this context. Hatch-Waxman requires that the regulatory approval at issue must have been for the first commercial marketing or use of the ‘product,’ which is expressly defined by Hatch-Waxman as ‘the active ingredient of a new drug, including any salt or ester of the active ingredient.’ A patent claiming a metabolite of an approved drug does not claim the approved drug. A patent claiming a prodrug form where the active moiety is different requires careful analysis. The claim must, in a technically accurate sense, cover the thing that FDA approved.<\/p>\n\n\n\n

Second, only one patent per regulatory review period can receive a PTE. If a company holds multiple patents that each claim the approved product \u2014 for instance, a composition-of-matter patent and a method-of-use patent that each cover the approved active ingredient \u2014 it can extend only one. The selection decision is significant and is discussed in strategic detail below.<\/p>\n\n\n\n

Third, the patent must not have previously been extended under Section 156 for a different product. A restoration period cannot be obtained for agency review of a subsequently approved drug covered by the same patent whose marketing also is delayed for reasons of FDA procedures; such term extension would not cover the subsequent drug.<\/p>\n\n\n\n

Fourth, the application must be filed within 60 days of FDA approval. This is a hard deadline. There is no provision for late filing, and the courts have consistently refused to equitably toll the deadline. A company whose legal or regulatory affairs team misses the 60-day window loses the PTE permanently.<\/p>\n\n\n\n

The Due Diligence Requirement<\/strong><\/h3>\n\n\n\n

The PTE doctrine is not designed to provide blanket compensation for the entire period of regulatory review of a product. The applicant for PTE must demonstrate that it exercised due diligence during the review period. Through this requirement, Hatch-Waxman provides an incentive for drug manufacturers to take an active role in pursuing regulatory approval once an IND application is made effective by the FDA in order to maximize the available extension period.<\/p>\n\n\n\n

The due diligence requirement trims the regulatory review period that counts toward the PTE calculation. If the FDA determines that the applicant failed to pursue approval with reasonable diligence during any part of the testing phase, those periods are excluded. The FDA publishes its determination of the regulatory review period in the Federal Register, after which any third party \u2014 including a generic competitor waiting to file an ANDA \u2014 has 180 days to file a due diligence petition challenging the calculation.<\/p>\n\n\n\n

Generic manufacturers routinely file these petitions on commercially significant drugs. The challenge strategy is straightforward: if the due diligence challenge succeeds, it shortens the PTE, pulling forward the effective date of patent expiration and accelerating the generic’s ability to launch. For a high-revenue drug, the difference between a fully unchallenged PTE and a PTE reduced by a successful due diligence petition can translate directly into competitive entry months or years earlier.<\/p>\n\n\n\n

Scope of an Extended Patent<\/strong><\/h3>\n\n\n\n

The extension granted under Section 156 is narrower than the original patent’s full scope. The scope of any extension is limited to the product or process that is the subject of agency review. This means that during an extension period of the patent term, competitors may practice claims of the invention that were not the subject of the regulatory review process.<\/p>\n\n\n\n

For a composition-of-matter patent claiming a broad genus, the extension only enforces the claims against the specific approved product \u2014 the specific compound, not the entire genus. A competitor that manufactures a different member of the same genus during the extension period does not infringe the extended patent, even if the genus claim would cover their product under normal circumstances. This scope limitation is critical for portfolio strategy. It means that a broad composition-of-matter patent, once extended, provides narrower effective protection than the same patent in its original unexpired term.<\/p>\n\n\n\n

\n\n\n\n

Patent Term Adjustment Under 35 U.S.C. \u00a7 154(b): The Prosecution-Side Mechanism<\/strong><\/h2>\n\n\n\n

The AIPA Framework and Its Three Delay Categories<\/strong><\/h3>\n\n\n\n

PTA was established by the American Inventors Protection Act of 1999 and codified at 35 U.S.C. \u00a7 154(b) as a way to balance unreasonable delays caused by the USPTO and applicants during examination of a non-provisional patent application, such that, if warranted, an applicant could gain additional patent term \u2014 that is, effective patent term could be extended past 20 years from an application’s earliest effective filing date.<\/p>\n\n\n\n

Unlike PTE, PTA does not require a separate application or a specific triggering event like FDA approval. It accrues automatically during patent prosecution based on documented delays, and the USPTO lists the final PTA amount on the face of the issued patent. But automatic calculation does not mean accurate calculation, as the September 2024 USPTO coding error demonstrated.<\/p>\n\n\n\n

35 U.S.C. \u00a7 154(b) defines three kinds of examination delays: ‘A’ delay, ‘B’ delay, and ‘C’ delay. The USPTO must provide notice regarding a newly-filed application within 14 months of its filing date for standard U.S.-origin applications, and thereafter the USPTO should respond to a reply or an appeal within 4 months and issue the patent within 4 months of issue payment.<\/p>\n\n\n\n

The three categories operate as follows:<\/p>\n\n\n\n

‘A’ delay covers specific failure-to-act periods. If the USPTO fails to issue a first Office Action within 14 months of filing, the applicant accumulates one PTA day for each day the Office Action was late. The same applies if the USPTO takes more than four months to respond to an applicant’s reply, or more than four months to issue the patent after payment of the issue fee. Each of these sub-periods is tracked separately.<\/p>\n\n\n\n

‘B’ delay covers the overall pendency guarantee. If the patent has not issued within three years of the filing date, ‘B’ delay begins accruing at one day per day until the patent issues. This three-year pendency guarantee is the mechanism that makes prosecution timing a direct financial variable. For pharmaceutical patents with complex prosecution histories, PTA adjustments of 12 to 36 months are common.<\/p>\n\n\n\n

‘C’ delay covers interference, secrecy order, and appeal periods where appellate bodies have taken excessive time to act. This is the least commonly relevant category in pharmaceutical prosecution.<\/p>\n\n\n\n

The three categories can overlap, and Congress specified that overlapping periods cannot be double-counted. Total PTA equals A delay plus B delay plus C delay minus overlap minus applicant delay.<\/p>\n\n\n\n

Applicant Delay and the Response-Timing Trap<\/strong><\/h3>\n\n\n\n

Applicant delay is the offset side of the PTA calculation. It subtracts from whatever PTA the USPTO generated. Applicant delay accrues when the applicant fails to respond to an Office Action within three months. Every day beyond three months in responding to a USPTO action generates one day of applicant delay that cancels one day of PTA.<\/p>\n\n\n\n

Applicant delay includes any day the applicant failed to respond to a USPTO action within three months. If the USPTO issues an office action and the applicant takes five months to respond, two months of applicant delay are subtracted from the accumulated PTA. This offset rule is significant for pharmaceutical prosecution strategy: applicants who allow office actions to go unanswered for extended periods to manage workload or costs forfeit the PTA days that accumulate during that delay.<\/p>\n\n\n\n

For small molecule drugs with relatively straightforward patent prosecution, the PTA amounts tend to be modest \u2014 a few hundred days at most. For biologics and complex pharmaceutical inventions where prosecution involves extensive claim amendments, multiple office actions, and continuation strategies, PTA accumulations of two to four years are common. A drug generating $10 million per day in revenue that recovers 60 days of PTA from a USPTO delay pattern receives $600 million in additional commercial value at no incremental R&D cost.<\/p>\n\n\n\n

The September 2024 USPTO Coding Error: A Real-World Lesson<\/strong><\/h3>\n\n\n\n

In September 2024, the USPTO disclosed a software coding error that had affected PTA calculations for patents issued between March 19, 2024 and July 30, 2024. The error may have caused an incorrect calculation of delay under 35 U.S.C. 154(b)(1)(A) (‘A’ delay) and the amount of overlap under 35 U.S.C. 154(b)(2)(A) (‘Overlap’). The USPTO states no other PTA calculations were affected. Although the USPTO estimates about 1% of all patents issued from March 19, 2024, through July 30, 2024, were impacted by this error, it would be advisable for all patentees issued a patent within that timeframe to check their PTA calculation quickly.<\/p>\n\n\n\n

To revise a PTA determination stemming from this coding error, a request for reconsideration may be filed without a fee within seven months of the date the patent was granted. The USPTO will waive both the request for reconsideration fee and any extension of time fees.<\/p>\n\n\n\n

The coding error is instructive beyond its specific period. It confirms that USPTO PTA calculations are not infallible and that pharmaceutical companies need active monitoring processes rather than passive reliance on whatever the patent face page reports. For a blockbuster drug, the difference between an accurate PTA and an understated PTA can represent hundreds of millions of dollars. The USPTO’s fee waiver for the 2024 coding error was a concession that the error was systemic, not applicant-specific, but the broader lesson is that every pharmaceutical patent with significant PTA deserves independent verification.<\/p>\n\n\n\n

\n\n\n\n

How PTA and PTE Interact: Stacking, Capping, and the Critical Difference<\/strong><\/h2>\n\n\n\n

The Mechanics of Stacking<\/strong><\/h3>\n\n\n\n

PTA and PTE are both statutory mechanisms for extending patent term, but they operate in different dimensions and are calculated independently. PTA extends the nominal 20-year term upward based on prosecution delays. PTE adds an additional extension on top of the PTA-adjusted term based on FDA regulatory delay.<\/p>\n\n\n\n

The term of a patent which claims a product, a method of using a product, or a method of manufacturing a product shall be extended in accordance with this section from the original expiration date of the patent, which shall include any patent term adjustment granted under section 154(b).<\/p>\n\n\n\n

This statutory stacking means that PTA and PTE compound. A patent with two years of PTA has an adjusted expiration date two years later than the nominal 20-year term. When PTE is calculated, it attaches to that PTA-adjusted expiration date. If the PTE calculation yields four additional years, the final expiration date is the nominal 20-year term plus two years of PTA plus four years of PTE. The 14-year post-approval cap under Section 156 applies to this stacked total, capping the PTE portion if necessary.<\/p>\n\n\n\n

The Key Asymmetry in Double Patenting Analysis<\/strong><\/h3>\n\n\n\n

The stacking benefit creates a significant asymmetry that generic manufacturers have tried to exploit through obviousness-type double patenting (ODP) challenges. The logic of the ODP challenge is straightforward: if a patent receives significant PTA and expires later than a related patent in the same family, the later-expiring patent unjustifiably extends exclusivity over obvious variants of the same invention.<\/p>\n\n\n\n

In Cellect, the Federal Circuit held that patent term extension (PTE) and patent term adjustment (PTA) are not the same for purposes of an ODP analysis and that ‘ODP for a patent that has received PTA, regardless whether or not a terminal disclaimer is required or has been filed, must be based on the expiration date of the patent after PTA has been added.’<\/p>\n\n\n\n

The Cellect ruling, issued in August 2023 and confirmed when the Federal Circuit denied en banc rehearing in January 2024 and the Supreme Court denied certiorari in October 2024, established that PTA-extended patent terms are included in ODP analysis. This threatened to make PTA awards for patent families with multiple members vulnerable to invalidity challenges based on earlier-expiring sibling patents.<\/p>\n\n\n\n

Allergan v. MSN: The 2024 Limiting Principle<\/strong><\/h3>\n\n\n\n

The Federal Circuit pulled back from the full implications of Cellect in August 2024 with its decision in Allergan USA v. MSN Laboratories. On August 13, 2024, the Federal Circuit held that ‘a first-filed, first-issued, later-expiring claim cannot be invalidated by a later-filed, later-issued, earlier-expiring reference claim having a common priority date.’<\/p>\n\n\n\n

The case arose from ANDA litigation involving Allergan’s Viberzi (eluxadoline) tablets. Sun argued that claim 40 of the ‘356 patent was invalid for ODP over claim 33 of the ‘011 patent and claim 5 of the ‘709 patent because the claims are not patentably distinct and because claim 40, having been awarded 467 days of PTA, expires after the reference claims of the ‘011 and ‘709 patents.<\/p>\n\n\n\n

The Federal Circuit reversed the district court’s invalidity finding. ‘To hold otherwise \u2014 that a first-filed, first-issued parent patent having duly received PTA can be invalidated by a later-filed, later-issued child patent with less, if any, PTA \u2014 would not only run afoul of the fundamental purposes of ODP, but effectively abrogate the benefit Congress intended to bestow on patentees when codifying PTA.’<\/p>\n\n\n\n

The rule from Allergan is that the first-filed, first-issued patent in a family ‘sets the maximum period of exclusivity for the claimed subject matter and any patentably indistinct variants.’ A later-filed, later-issued child patent cannot be an ODP reference against the parent, even if the parent expires later due to PTA. Allergan brings clarity to the ODP doctrine by confirming that patent filing and issue dates, in addition to expiration dates, are relevant to analyzing ODP.<\/p>\n\n\n\n

The practical consequence is significant. For pharmaceutical patent families where the parent application was filed first and the continuation applications were filed later, PTA on the parent patent is now protected from ODP challenge based on the continuation siblings. The first-filed, first-issued patent in a family often receives the most PTA, and now cannot be invalidated for ODP over any subsequent patents in the same family. It often may be desirable to pursue the most critical subject matter in this first patent.<\/p>\n\n\n\n

\n\n\n\n

The Merck Bridion Decision: A PTE Case Study in Reissue Strategy<\/strong><\/h2>\n\n\n\n

The Facts of Merck Sharp & Dohme B.V. v. Aurobindo Pharma USA, Inc.<\/strong><\/h3>\n\n\n\n

The Federal Circuit’s March 13, 2025 decision in this case resolved a question that had significant implications for pharmaceutical companies that pursue reissue patents during FDA review: when a patent is reissued, from which date \u2014 the original issue date or the reissue date \u2014 should the PTE calculation begin?<\/p>\n\n\n\n

The facts are precise and worth following exactly. Merck’s ‘340 patent covering sugammadex, the active ingredient in BRIDION, was issued on December 30, 2003. Merck applied for a reissue patent while sugammadex was under regulatory review, adding 12 narrower claims. The reissue patent was issued as the RE’733 patent on January 28, 2014, and sugammadex was approved by the FDA on December 15, 2015. The USPTO granted Merck’s request for a five-year patent term extension \u2014 the maximum allowed under Section 156(c) \u2014 based on the ‘340 patent’s original issue date.<\/p>\n\n\n\n

The commercial stakes were direct. According to Aurobindo, if the reissue date rather than the original issue date were used to calculate PTE, the proper length of PTE should be 686 days, not five years (or 1,825 days). The difference between 686 days and 1,825 days of PTE extension on a significant surgical reversal drug represents substantial revenue and a correspondingly large difference in the competitive window for generic manufacturers.<\/p>\n\n\n\n

The Federal Circuit’s Holding and Its Rationale<\/strong><\/h3>\n\n\n\n

Addressing the calculation of patent term extensions under the Hatch-Waxman Act, the Federal Circuit affirmed a district court decision that under the act the issue date of the original patent should be used to calculate the extension, not the reissue date.<\/p>\n\n\n\n

The sole issue on appeal was whether a PTE for a reissued patent should be calculated based on the issue date of the original patent or the reissued patent. Aurobindo argued that, under subsection 156(c)’s plain meaning, ‘the patent’ refers to the reissued patent, since ‘the patent eligible for extension’ is the reissued patent. Merck urged the opposite interpretation, arguing that subsection 156(c)’s text, together with other patent statutes and the history of patent reissue, demonstrated that subsection 156(c) refers to the original issue date. The USPTO filed a brief in support of Merck.<\/p>\n\n\n\n

The Federal Circuit agreed with Merck and the USPTO. By essentially preserving PTE awarded to original patents, this decision could encourage pharmaceutical companies to pursue reissue, especially if there are any concerns that broad original claims may not comply with the court’s recent Orange Book listing guidance. For patents that disclose but do not expressly claim the approved active ingredient, seeking a reissue patent could allay Orange Book listability concerns. The PTE decision in Merck indicates that obtaining a reissued patent would not lessen PTE, providing further reason to consider the reissue process as an opportunity to strengthen a patent portfolio.<\/p>\n\n\n\n

What the Decision Means for Reissue Strategy<\/strong><\/h3>\n\n\n\n

The practical upshot is that pharmaceutical companies that are concerned about their original patent’s claim breadth \u2014 whether for Orange Book listability or for enforcement purposes in ANDA litigation \u2014 can pursue reissue to add narrower claims expressly reciting the approved active ingredient without sacrificing PTE. Before this decision, some companies were reluctant to reissue during FDA review because of the risk that the reissue date would be used as the PTE anchor, dramatically shortening the available extension.<\/p>\n\n\n\n

Cancellation of claims covering drug products under regulatory review in a reissue patent will result in forfeiture of any patent term extension. The corollary of the Federal Circuit’s holding is that the protection extends only when the original patent included the same claims directed to the drug product subject to FDA review. A company that reissues and in the process removes the claims that originally covered the approved active ingredient would lose the benefit of the original issue date for PTE calculation purposes.<\/p>\n\n\n\n

The decision also confirms that the USPTO’s long-standing practice of calculating PTE from the original issue date for reissued patents was correct. The amicus brief that the USPTO filed in support of Merck reflected the agency’s investment in preserving the stability of its own administrative practice, and the Federal Circuit’s affirmance gives that practice precedential backing.<\/p>\n\n\n\n

\n\n\n\n

Strategic Patent Selection: Choosing Which Patent to Extend<\/strong><\/h2>\n\n\n\n

The One-Patent Constraint<\/strong><\/h3>\n\n\n\n

Only one patent per approved product qualifies for PTE, it must be a patent that claims the approved active ingredient or a method of using it, and the application must be filed within 60 days of approval. The choice of which patent to extend, where the portfolio includes multiple eligible patents, is one of the most consequential strategic decisions a pharmaceutical company makes during the approval process.<\/p>\n\n\n\n

Most large pharmaceutical companies hold several patents that could potentially qualify for PTE on a given product. A typical NDA may be covered by a composition-of-matter patent on the active ingredient, one or more method-of-use patents on specific therapeutic applications, a formulation patent on the approved dosage form, and potentially a process patent on the manufacturing method. All of these may be listed in the Orange Book for the approved product. Only one can receive a PTE.<\/p>\n\n\n\n

The selection logic involves two primary factors: the remaining term of each eligible patent at the time of approval, and the scope of protection each patent provides in the extended term.<\/p>\n\n\n\n

A patent with less remaining term at the time of approval generates a longer PTE award (more regulatory review period falls after the patent issued, so more time is compensable), subject to the five-year cap. A patent with substantial remaining term generates a shorter PTE (some of the regulatory review period is offset by the pre-expiration term). For a patent family where the composition-of-matter patent was filed early in the discovery program and the method-of-use patents were filed later based on clinical findings, the composition patent often has less remaining term at approval and thus generates the maximum or near-maximum extension.<\/p>\n\n\n\n

The scope consideration cuts the other direction. A composition-of-matter patent extended under Section 156 provides protection only against the specific approved compound, not the full genus. If competitors could make and sell closely related compounds that fall within the original genus but are not the approved active ingredient, the composition patent’s extended protection is narrower than its original scope. A method-of-use patent covering a broad treatment indication may provide more practical commercial protection during the extension period, even if it generates a shorter extension term.<\/p>\n\n\n\n

The Interaction with the Orange Book<\/strong><\/h3>\n\n\n\n

The Orange Book serves as the mechanism by which a patent listed under Section 156 extension generates the Paragraph IV litigation rights and 30-month stays that are central to the Hatch-Waxman enforcement framework. Only patents listed in the Orange Book trigger the Paragraph IV certification process and the associated 30-month stay of ANDA approval.<\/p>\n\n\n\n

The recent Federal Circuit guidance tightening Orange Book listing requirements \u2014 which requires patents to ‘particularly point out and distinctly claim’ the specific approved drug \u2014 intersects with the reissue strategy confirmed in the Bridion decision. A patent whose claims are broad enough to raise Orange Book listing questions may benefit from reissue to add specific claims, with the Bridion holding now confirming that the reissue does not reset the PTE calculation to the reissue date.<\/p>\n\n\n\n

\n\n\n\n

The Interplay with the 14-Year Post-Approval Cap<\/strong><\/h2>\n\n\n\n

When the Cap Bites<\/strong><\/h3>\n\n\n\n

The 14-year post-approval cap in Section 156(c)(3) limits total patent term after FDA approval, including any PTE, to 14 years. This cap can significantly reduce the effective PTE for drugs that go through relatively rapid regulatory review.<\/p>\n\n\n\n

Consider a drug whose composition-of-matter patent was filed in 2010 (20-year term to 2030) and received three years of PTA (adjusted expiration 2033). FDA approves the drug in 2022. At the time of approval, the remaining patent term after PTA is 11 years (2022 to 2033). The regulatory review period began with IND filing in 2012 and concluded with FDA approval in 2022, a total of ten years. Half the testing phase (six years from IND to NDA filing) plus the approval phase (two years from NDA to approval) yields seven years of eligible regulatory review period.<\/p>\n\n\n\n

Without the cap, the PTE would be 3.5 years (half the testing phase contributing 3 years, approval phase contributing 1 year, reaching the five-year maximum). But the post-approval term is 11 years, so the 14-year cap from approval would mean the total term with PTE is capped at 14 years from 2022, or a 2036 expiration. The uncapped calculation would yield 2033 plus five years, or 2038. The 14-year cap pulls the expiration back to 2036, effectively making the PTE three years instead of five.<\/p>\n\n\n\n

This calculation is why the patent selection decision matters strategically. If the same portfolio contains a method-of-use patent filed in 2015 (term to 2035, no PTA), the remaining term at 2022 approval is 13 years. The 14-year cap from approval extends to 2036. Now the method-of-use patent can receive a PTE that takes it to 2036 \u2014 only one year of extension \u2014 but the composition patent gets three years. The composition patent wins the PTE selection in this example, not because it has a longer extension period but because the 14-year cap interacts with the remaining terms to make the composition patent’s extension the dominant one.<\/p>\n\n\n\n

Real pharmaceutical portfolios are considerably more complex than this illustration, with multiple patents at different stages, variable PTA amounts, and Orange Book listing considerations that constrain which patents are eligible. The calculation described here is the bare framework; execution requires detailed modeling of every eligible patent in the portfolio.<\/p>\n\n\n\n

\n\n\n\n

The Patent Cliff Context: What PTE and PTA Are Protecting<\/strong><\/h2>\n\n\n\n

The Revenue Exposure That Makes These Calculations Urgent<\/strong><\/h3>\n\n\n\n

Between 2025 and 2030, more than $300 billion in prescription drug revenues will lose patent exclusivity, about one-sixth of the industry’s annual revenue. Nearly 200 drugs will see their patents expire in this window, including about 70 blockbusters generating over $1 billion each in annual sales. The previous patent cliff, in 2016, eroded about $100 billion in brand-name sales. The current one is three times that size.<\/p>\n\n\n\n

Against this backdrop, the value of properly claimed and defended PTE and PTA is not a technical legal matter. It is a financial planning imperative.<\/p>\n\n\n\n

Merck is leveraging additional compound patents that expire in 2029 due to patent term adjustments related to regulatory delays to extend Keytruda’s patent life. Although these patents, stemming from the original discovery of Keytruda’s active ingredient, may provide some protection, they are expected to face significant litigation.<\/p>\n\n\n\n

Merck’s U.S. Patent No. 8,354,509, which claims antibodies to the human PD-1 receptor, received a PTE of 393 days, extending its protection from mid-2027 into late 2028. Combined with other patents in the Keytruda estate, Merck’s total protection period for pembrolizumab extends through the early 2030s when all listed Orange Book patents and their PTEs are aggregated.<\/p>\n\n\n\n

Eliquis: PTA and PTE Working in Combination<\/strong><\/h3>\n\n\n\n

Eliquis (apixaban), a blockbuster anticoagulant jointly marketed by Bristol Myers Squibb and Pfizer, demonstrates how pharmaceutical companies can extend their patent protection and market monopoly in more ways than one. Through the current statutory systems of PTA and PTE, BMS and Pfizer have benefited from extending the patent term on its original compound patent, helping to delay the entry of generic versions of Eliquis.<\/p>\n\n\n\n

Eliquis (apixaban) generated about $13 billion in 2024 revenue. Generic entry is expected on April 1, 2028, following court rulings that delayed initial 2026 expectations. The difference between the 2026 and 2028 effective exclusivity dates illustrates precisely how litigation over PTE and PTA calculations plays out in commercial terms. Two additional years of exclusivity on a drug generating $13 billion annually represents approximately $26 billion in additional protected revenue \u2014 a figure that dwarfs the litigation costs involved in defending the extension.<\/p>\n\n\n\n

Bristol Myers Squibb’s apixaban (Eliquis), producing over $10 billion annually, sees its key U.S. patents expire between 2027 and 2029.<\/p>\n\n\n\n

Semaglutide: The First-to-Market Advantage of Getting PTE Right<\/strong><\/h3>\n\n\n\n

Novo Nordisk’s semaglutide portfolio illustrates both the commercial value of properly timed PTE applications and the complexity of managing PTE across reformulated and re-indicated products. Ozempic, Rybelsus and Wegovy are products based on the active ingredient and GLP-1 receptor agonist semaglutide, as developed and marketed by Novo Nordisk. Initially approved for type 2 diabetes management, semaglutide has been repositioned and rebranded across three products: Ozempic (injectable, for diabetes), Rybelsus (oral tablet, for diabetes), and Wegovy (injectable, higher dose, for obesity). Novo Nordisk has utilized PTA, PTE, and the creation of a patent thicket full of follow-on patents, to extend its patent protection.<\/p>\n\n\n\n

The complication for semaglutide’s PTE strategy is the ‘first commercial marketing’ requirement. Only the first regulatory approval of an active ingredient can anchor a PTE. Ozempic received FDA approval for type 2 diabetes management in December 2017. That approval anchors the PTE for the semaglutide composition patent. When Wegovy received its obesity indication approval in June 2021, that was not the first approval of semaglutide and therefore did not generate a separate PTE opportunity. This restriction is a reason why the active ingredient decision for PTE must be made at the time of the first approval, with awareness that subsequent formulations or indications for the same molecule will not be eligible.<\/p>\n\n\n\n

\n\n\n\n

Practical Calculation Framework: Regulatory Review Period Anatomy<\/strong><\/h2>\n\n\n\n

What Counts and What Doesn’t<\/strong><\/h3>\n\n\n\n

The regulatory review period, which is the basis for the PTE calculation, runs from IND effectiveness to NDA approval, but Congress built in important exclusions. The basic period includes half the time in the IND testing phase and all the time in the NDA approval phase, but certain pauses in the regulatory process are excluded from the eligible period.<\/p>\n\n\n\n

Specifically, periods during which the applicant failed to exercise due diligence \u2014 as determined through FDA’s due diligence review process \u2014 are excluded. Periods when the FDA placed the IND or NDA on clinical hold are excluded, because the hold is attributable to the applicant’s product rather than to the regulatory review process per se. And any period that preceded the IND effectiveness date is excluded, which is why the patent filing strategy needs to be coordinated with IND timing.<\/p>\n\n\n\n

The FDA calculates the regulatory review period and publishes it in the Federal Register. The USPTO then uses that published calculation to determine the PTE amount. Applicants who believe the FDA’s calculation is incorrect have the opportunity to challenge it through comment and petition processes, but these processes are rarely used in practice because the FDA’s calculations tend to be accurate on the factual record.<\/p>\n\n\n\n

Current valuation models for late-stage biotech assets prioritize the PTE calculation because even a 180-day extension can represent hundreds of millions of dollars in net present value.<\/p>\n\n\n\n

The 60-Day Filing Deadline in Practice<\/strong><\/h3>\n\n\n\n

The 60-day deadline for filing the PTE application runs from the date of FDA approval. This is not the date the approval letter is received, not the date the approval becomes effective, but the date FDA approves the NDA. For pharmaceutical companies managing multiple approval timelines, the 60-day clock can be easy to lose in the operational chaos of a major product launch.<\/p>\n\n\n\n

Best practice in the industry is to prepare the PTE application before FDA approval, so that the filing can be made within days of receiving the approval letter rather than using the full 60-day period. The application requires the patent number, the FDA approval number, a statement of eligibility including the first commercial marketing attestation, and payment of the government filing fee. None of these elements should require 60 days to assemble if the preparation has been done in advance. Companies that use the full 60 days as working time are introducing unnecessary risk into a process where a single missed deadline permanently forfeits the extension.<\/p>\n\n\n\n

\n\n\n\n

The USPTO Reconsideration Process: Challenging PTA Errors<\/strong><\/h2>\n\n\n\n

The Administrative Pathway<\/strong><\/h3>\n\n\n\n

A patentee dissatisfied with the USPTO’s PTA calculation may request reconsideration after the patent issues, which typically resolves any differences between the patentee’s and USPTO’s calculations. A patentee dissatisfied with the USPTO’s reconsideration decision also has the exclusive remedy of filing a civil action in the U.S. District Court for the Eastern District of Virginia within 180 days of the USPTO’s reconsideration decision.<\/p>\n\n\n\n

The reconsideration process is the standard first step when a company’s independent PTA calculation differs from what appears on the patent face page. The request must be filed within two months of patent issue (extendable by up to five months with fees) and must specifically identify the error in the USPTO’s calculation with reference to the statutory provisions and prosecution history.<\/p>\n\n\n\n

For many life science and pharmaceutical companies, each day of a patent term can translate into millions of dollars.<\/p>\n\n\n\n

The administrative reconsideration process resolves most PTA disputes without litigation. The USPTO reviews the prosecution history, recalculates the delays and offsets, and issues a decision. If the recalculation is still incorrect or inadequate, the patent holder must file a civil action in the Eastern District of Virginia \u2014 the exclusive venue for these challenges \u2014 within 180 days. This remedy, which is not commonly used, requires the patentee to meet the high burden of proving that the USPTO’s actions are ‘in excess of statutory jurisdiction, authority, or limitations,’ or are otherwise ‘arbitrary, capricious, an abuse of discretion, or otherwise not in accordance with law.’<\/p>\n\n\n\n

That is an APA standard, and it sets a high bar. Most patent holders who pursue the administrative reconsideration route and lose do not appeal to federal court. But for a blockbuster drug where the disputed PTA days represent hundreds of millions of dollars, the litigation cost is entirely justified by the revenue at stake.<\/p>\n\n\n\n

The Coding Error Lesson: Active Monitoring Required<\/strong><\/h3>\n\n\n\n

The September 2024 coding error was not an isolated incident. USPTO software systems calculate PTA using prosecution history data, and software errors in that calculation have occurred previously and will occur again. For pharmaceutical companies, the right operational response is to independently calculate expected PTA from prosecution history records, compare it against what appears on the issued patent, and file a reconsideration request within the two-month window if the numbers diverge.<\/p>\n\n\n\n

This is not a process that happens naturally without deliberate organizational effort. Patent prosecution teams need to be assigned the task, given the tools to perform the calculation, and given clear escalation paths when discrepancies are found. For large pharmaceutical portfolios with hundreds of patents issuing each year, this requires systematic workflow rather than ad hoc review.<\/p>\n\n\n\n

DrugPatentWatch tracks PTE grants published in the Federal Register and aggregates PTA data from issued patents, providing an independent reference point for companies validating their own calculations and for competitive intelligence teams modeling competitor exclusivity timelines. The platform’s aggregation of Orange Book data, PTE certificate status, and Paragraph IV challenge records gives IP teams and analysts a single source for the complete exclusivity picture rather than a manual synthesis of FDA, USPTO, and Federal Register data.<\/p>\n\n\n\n

\n\n\n\n

International Counterparts: SPCs in Europe and Patent Term Extension in Japan<\/strong><\/h2>\n\n\n\n

The European Supplementary Protection Certificate<\/strong><\/h3>\n\n\n\n

The European Union’s Supplementary Protection Certificate (SPC) is the closest functional equivalent to the U.S. PTE, but it differs in structure, calculation, and litigation risk profile. An SPC grants up to five years of additional protection beyond the basic patent term, plus a potential six-month extension for pediatric studies. The SPC attaches to a specific ‘basic patent’ that the holder designates from among the patents covering the approved product.<\/p>\n\n\n\n

Unlike the U.S. system where PTE is granted by the USPTO based on FDA regulatory review period, SPC protection in Europe is granted by national patent offices in each EU member state based on the EU marketing authorization date. This national fragmentation means that a pharmaceutical company seeking SPC protection in 27 EU member states must file 27 separate applications, each subject to the local rules of that national office. The European Patent Office coordinates through the Unitary Patent system for new patents as of June 2023, but existing SPCs remain governed by national systems.<\/p>\n\n\n\n

SPC litigation in Europe has been extensive and increasingly technical. The Court of Justice of the European Union has issued numerous references defining what constitutes the ‘active ingredient’ of the authorized product for SPC purposes, which determines whether combination products, prodrugs, and metabolites can anchor an SPC. The Neurim doctrine, which once allowed SPCs for new uses of known active ingredients, was significantly restricted by the CJEU’s ruling in Neurim v. Sandoz in 2023, limiting SPC availability to first authorizations of the basic patent.<\/p>\n\n\n\n

For pharmaceutical companies managing global exclusivity, the U.S. PTE strategy and the European SPC strategy need to be coordinated from patent filing through regulatory approval. The choice of which patent to designate as the SPC basic patent has implications analogous to the U.S. PTE patent selection decision, with similar tradeoffs between remaining term and claim scope.<\/p>\n\n\n\n

Japan’s Patent Term Extension<\/strong><\/h3>\n\n\n\n

Japan operates a patent term extension system under Article 67(2) of the Japanese Patent Act that is structurally similar to the U.S. PTE. Extensions of up to five years are available for patents covering drugs and agrochemicals, with the extension calculated based on the period when the invention could not be worked due to regulatory review. Japan’s system has generated its own litigation over what constitutes an eligible patent and how the regulatory review period is calculated, with the Japanese Intellectual Property High Court issuing significant rulings on these questions in recent years.<\/p>\n\n\n\n

The Japan system is notable for its ‘first approval’ limitation that parallels the U.S. rule. A patent can only receive a PTE based on a regulatory review period for the first marketing approval in Japan. Subsequent approvals for new formulations or indications of the same active ingredient do not generate new PTE eligibility.<\/p>\n\n\n\n

\n\n\n\n

Pediatric Exclusivity: The Six-Month Bonus<\/strong><\/h2>\n\n\n\n

How Pediatric Exclusivity Interacts with PTE and PTA<\/strong><\/h3>\n\n\n\n

Pediatric exclusivity extends all existing patent terms and exclusivity periods for the drug by six months. A compound patent expiring in March 2026 gets extended to September 2026 if PE is awarded. NCE exclusivity expiring in January 2024 gets extended to July 2024. The extension applies uniformly to all listed patents and exclusivities.<\/p>\n\n\n\n

Pediatric exclusivity is granted when a company completes FDA-requested pediatric studies under the Best Pharmaceuticals for Children Act. Unlike PTE, which applies to a single selected patent, pediatric exclusivity adds six months to every patent and regulatory exclusivity listed in the Orange Book for the drug. This makes it uniquely powerful: it is the only mechanism that simultaneously extends every protection rather than a single selected right.<\/p>\n\n\n\n

The economic analysis of the pediatric exclusivity program estimated average revenue per pediatric exclusivity award in the range of $450 million for top-selling products in the early 2000s. For a blockbuster generating $10 billion or more annually today, the value of six months of additional exclusivity across all Orange Book protections is substantially higher than that estimate.<\/p>\n\n\n\n

The pediatric studies required to earn the exclusivity are typically less expensive than the pivotal trials that supported original approval. For the manufacturers of products approaching key patent cliffs, completing pediatric studies and requesting pediatric exclusivity is often one of the highest-ROI investments available \u2014 a relatively modest clinical commitment that protects against revenue erosion across the entire patent portfolio for the product.<\/p>\n\n\n\n

\n\n\n\n

Common Errors and How to Avoid Them<\/strong><\/h2>\n\n\n\n

The Four Most Expensive Mistakes<\/strong><\/h3>\n\n\n\n

Four patterns of error appear repeatedly in PTE and PTA practice, each with material financial consequences:<\/p>\n\n\n\n

Missing the 60-day filing window is the most catastrophic and most preventable. There is no cure. The PTE is gone. Setting calendar reminders keyed to the FDA approval letter date, with backup escalation paths if the primary attorney is unavailable, is the minimum operational safeguard.<\/p>\n\n\n\n

Failing to verify PTA against an independent calculation is the second most common and second most costly. The USPTO calculation appears authoritative because it is on the patent face page, but it is generated by software from prosecution history data, and that software has a documented error history. Every pharmaceutical patent issued with PTA should have its calculation verified against the prosecution history before the two-month reconsideration window closes.<\/p>\n\n\n\n

Selecting the wrong patent for PTE based on term remaining without modeling scope is a strategic error rather than a procedural one, but it can be equally costly. The narrowed scope of a PTE-extended patent means that competitors can work non-approved members of a genus claim without infringement during the extension period. A company that selects a broad genus patent for PTE without considering this scope narrowing may find that the extension provides less practical protection than a method-of-use patent with a shorter extension period would have.<\/p>\n\n\n\n

Drug companies should be aware that if a parent compound has been approved, PTE will not be available for patents covering new uses of that parent compound or its salt or ester forms, even if the approved indication is wholly unrelated to ongoing research and development. This restriction surprises companies developing a second indication for an already-approved active ingredient. The PTE clock for that molecule has already run and cannot run again.<\/p>\n\n\n\n

Terminal Disclaimer Interactions<\/strong><\/h3>\n\n\n\n

A terminal disclaimer filed to overcome an ODP rejection during patent prosecution caps the extended term at the expiration date of the referenced patent. Under 35 U.S.C. \u00a7 154(b)(2)(B), PTA cannot push a patent beyond the date set by a terminal disclaimer. This creates a direct conflict with PTA accumulation for patents in a family where terminal disclaimers were filed during prosecution: PTA that would otherwise extend the term is lost to the terminal disclaimer cap.<\/p>\n\n\n\n

35 U.S.C. \u00a7 154(b)(2)(B) provides that a patent cannot be adjusted beyond the date set by the disclaimer.<\/p>\n\n\n\n

This interaction requires careful modeling at the prosecution stage. When a continuation application faces an ODP rejection, the choice between filing a terminal disclaimer to overcome the rejection and arguing against obviousness is not purely a validity question. It is also a PTA question: the terminal disclaimer surrenders the PTA extension that the continuation would otherwise accumulate, and for a high-revenue drug, that forfeited PTA may be worth more than the cost of the obviousness argument.<\/p>\n\n\n\n

\n\n\n\n

The Evergreening Debate and Its Regulatory Implications<\/strong><\/h2>\n\n\n\n

Where Legitimate Extension Ends and ‘Evergreening’ Begins<\/strong><\/h3>\n\n\n\n

PTE and PTA are both legitimate statutory mechanisms, and their proper use does not constitute evergreening in any meaningful legal or ethical sense. Evergreening, as critics and regulators use the term, typically refers to strategies that extend market exclusivity through incremental secondary patents covering formulations, metabolites, or minor modifications rather than through the statutory extension mechanisms designed for that purpose.<\/p>\n\n\n\n

PTA and PTE mechanisms delay the entry of generic medicines and add billions in additional revenue for blockbuster drugs, even before accounting for any extended market monopoly as a result of follow-on patenting.<\/p>\n\n\n\n

The policy tension is real. From the perspective of pharmaceutical manufacturers, PTE and PTA are congressionally designed compensation for time lost to regulatory and administrative delay. From the perspective of payers, generic manufacturers, and patient advocates, any extension of exclusivity delays access to lower-cost competition. The Inflation Reduction Act’s drug pricing negotiation provisions, which targeted the ten highest-spending Medicare drugs in their first round and included drugs whose effective exclusivity had been significantly shaped by PTE and PTA, reflect a legislative response to this tension.<\/p>\n\n\n\n

The distinction between PTE and PTA on one side \u2014 statutory rights earned by compliance with regulatory and administrative processes \u2014 and secondary patent strategies on the other is important for pharmaceutical companies to maintain in their public positioning and regulatory engagement. Using secondary patents to block generic competition while simultaneously pursuing PTE and PTA creates a combined exclusivity picture that invites legislative and regulatory scrutiny, even when each individual tool is lawfully used.<\/p>\n\n\n\n

\n\n\n\n

Building the Operational Framework: IP Team Requirements<\/strong><\/h2>\n\n\n\n

What the Function Needs to Execute<\/strong><\/h3>\n\n\n\n

Properly capturing PTE and PTA value across a pharmaceutical portfolio requires a dedicated operational function, not an ad hoc process managed by outside counsel alone. The elements are:<\/p>\n\n\n\n

Pre-IND patent filing strategy that sequences the composition-of-matter, method-of-use, and formulation patents to maximize PTA accumulation on the earliest filings while positioning the portfolio for PTE selection at approval. This requires IP team involvement from the earliest stages of the discovery program, not at the NDA stage when the portfolio structure is already fixed.<\/p>\n\n\n\n

Real-time PTA tracking during prosecution, with independent calculation of accruing PTA days and immediate flagging of USPTO response failures that generate ‘A’ delay. Patent prosecution management systems that integrate with USPTO patent center data can automate this tracking, but they require configuration and ongoing maintenance.<\/p>\n\n\n\n

NDA coordination to ensure that the IP team has advance notice of anticipated approval dates. The 60-day PTE window does not allow for a comfortable process if the IP team learns of approval from a news release rather than from an internal regulatory affairs alert.<\/p>\n\n\n\n

Post-issuance verification of both PTA amounts and PTE certificates. The verification should occur within the first two months after issuance (for PTA reconsideration) and should include modeling of the 14-year cap, scope implications, and interaction with terminal disclaimers.<\/p>\n\n\n\n

Litigation readiness for Paragraph IV challenges, which are a predictable feature of the Hatch-Waxman landscape for any commercially significant drug. The IP team needs to be prepared to defend both the underlying patent validity and the PTE calculation against generic manufacturers who will scrutinize both.<\/p>\n\n\n\n

\n\n\n\n

Using DrugPatentWatch for Competitive PTE Intelligence<\/strong><\/h2>\n\n\n\n

Competitive intelligence on PTE and PTA is a material advantage for both generic manufacturers planning ANDA filing strategies and branded manufacturers monitoring competitor exclusivity timelines. For every drug on your watch list, you need to build a complete dossier of its intellectual property and regulatory protections. Start with the Orange Book to pull the list of all patents submitted by the manufacturer. For each patent number, look it up in the USPTO database for Patent Term Adjustment (PTA). A tool like DrugPatentWatch becomes a massive time-saver in this process.<\/p>\n\n\n\n

DrugPatentWatch aggregates FDA Orange Book listings, PTE certificates from the Federal Register, patent expiration data from the USPTO, and Paragraph IV certification history into a single reference. For a generic manufacturer evaluating the ANDA filing opportunity on a given drug, the platform allows rapid identification of which patents are extended, by how much, and what the effective exclusivity window looks like after all extensions are applied. For a branded manufacturer, the same data enables modeling of competitor pipeline threats.<\/p>\n\n\n\n

For drugs still in NDA review, estimate the likely PTE by calculating the regulatory review period from publicly available IND and NDA filing dates. A drug with a 2027 nominal composition patent expiry that receives a 3-year PTE has a 2030 effective expiry, a difference that can shift DCF valuation by 15 to 25% for high-revenue assets.<\/p>\n\n\n\n

Buy-side analysts and institutional investors also use PTE and PTA data to refine LOE models. Buy-side analysts frequently calculate LOE dates using the patent’s nominal 20-year expiry without adjusting for PTA. For pharmaceutical patents with complex prosecution histories, PTA adjustments of 12 to 36 months are common. Checking issued pharmaceutical patents for their listed PTA amounts and incorporating those adjustments into LOE models is a straightforward source of analytical edge.<\/p>\n\n\n\n

\n\n\n\n

Looking Ahead: Legislative and Regulatory Pressures<\/strong><\/h2>\n\n\n\n

IRA Pricing Negotiation and the Value of Extended Exclusivity<\/strong><\/h3>\n\n\n\n

The Inflation Reduction Act’s drug price negotiation provisions directly intersect with the exclusivity framework that PTE and PTA help maintain. CMS negotiated its first tranche of 10 drugs in 2023-2024, targeting the highest-spending Medicare Part D drugs. The list included Eliquis (apixaban), Jardiance (empagliflozin), Xarelto (rivaroxaban), Januvia (sitagliptin), Farxiga (dapagliflozin), Entresto (sacubitril\/valsartan), Enbrel (etanercept), Imbruvica (ibrutinib), Stelara (ustekinumab), and Fiasp\/NovoLog insulin products. The negotiated MFPs published in August 2024 reflected discounts of 38-79% from the drugs’ list prices.<\/p>\n\n\n\n

The IRA’s drug selection criteria explicitly consider the years of market exclusivity remaining. Small-molecule drugs become eligible for negotiation after nine years of market exclusivity; biologics after 13 years. PTE can push a drug past these eligibility thresholds, delaying IRA negotiation by the length of the extension. For a high-revenue small-molecule drug whose effective exclusivity \u2014 including PTE and PTA \u2014 extends past the nine-year mark from approval, this is a direct financial consequence of properly executed patent term strategy.<\/p>\n\n\n\n

Congressional Scrutiny of Patent Term Mechanisms<\/strong><\/h3>\n\n\n\n

According to a 2025 paper in the Journal of Economic Perspectives, the net result of the Act is ‘a convoluted and expensive approach to balancing innovation and competition.’<\/p>\n\n\n\n

Congressional interest in modifying the PTE and PTA frameworks as part of drug pricing legislation is a persistent background risk for pharmaceutical companies that have built their exclusivity strategies around these mechanisms. Proposals to cap secondary patents, limit PTE to composition-of-matter patents, or accelerate the due diligence petition process have circulated in various legislative proposals without enactment. The Preserve Access to Affordable Generics and Biosimilars Act, reintroduced in April 2025 by Senators Klobuchar and Grassley, targets aspects of the patent settlement framework but illustrates the continuing legislative interest in narrowing the exclusivity tools available to branded manufacturers.<\/p>\n\n\n\n

For pharmaceutical IP teams, monitoring legislative proposals that could affect PTE and PTA is as important as monitoring litigation outcomes. A statutory change to the 14-year cap, the five-year maximum, or the due diligence framework would require rapid portfolio-wide reassessment of exclusivity timelines and competitive strategy.<\/p>\n\n\n\n

\n\n\n\n

Key Takeaways<\/strong><\/h2>\n\n\n\n

PTE under 35 U.S.C. \u00a7 156 and PTA under 35 U.S.C. \u00a7 154(b) are complementary mechanisms that operate in different dimensions: PTE compensates for FDA regulatory delay, PTA compensates for USPTO prosecution delay. Both must be actively managed to capture full value.<\/p>\n\n\n\n

The 60-day PTE filing window from FDA approval is a hard deadline with no equitable relief. Preparation must begin before approval, with filing ready to execute within days of the approval letter.<\/p>\n\n\n\n

The Federal Circuit’s March 2025 decision in Merck v. Aurobindo confirmed that PTE for reissued patents is calculated from the original patent’s issue date, enabling pharmaceutical companies to pursue reissue to strengthen Orange Book-listed claims without forfeiting PTE.<\/p>\n\n\n\n

In re Cellect established that PTA-adjusted expiration dates are included in ODP analysis. Allergan v. MSN qualified that holding by protecting first-filed, first-issued parents from ODP challenges based on later-filed, later-issued sibling patents. Patent families should be structured with awareness of both rules.<\/p>\n\n\n\n

Patent selection for PTE requires modeling both remaining term and effective scope during the extension period. The narrowed scope of Section 156 extension makes composition-of-matter patents less broadly protective during the extension period than during their original term.<\/p>\n\n\n\n

The USPTO’s September 2024 coding error demonstrated that PTA calculations on issued patents are not infallible. Independent verification within the two-month reconsideration window is operationally necessary for high-value pharmaceutical patents.<\/p>\n\n\n\n

Terminal disclaimers filed to overcome ODP rejections during prosecution cap PTA accumulation, creating a direct tradeoff between avoiding ODP invalidity and preserving full PTA value.<\/p>\n\n\n\n

DrugPatentWatch provides the competitive intelligence infrastructure for tracking PTE, PTA, and effective exclusivity across both proprietary portfolios and competitor pipelines, with data that directly informs LOE modeling, ANDA timing decisions, and M&A due diligence.<\/p>\n\n\n\n

The Inflation Reduction Act’s drug pricing negotiation provisions create a direct financial consequence of extended exclusivity: PTE can delay CMS negotiation eligibility by the length of the extension, adding a new dimension to PTE’s commercial value beyond market exclusivity alone.<\/p>\n\n\n\n

\n\n\n\n

FAQ<\/strong><\/h2>\n\n\n\n

Q: Can a pharmaceutical company receive both PTA and PTE for the same patent, and how do the two extensions stack?<\/strong><\/p>\n\n\n\n

Yes, and the stacking is additive with PTE applied on top of the PTA-adjusted expiration date. Section 156 explicitly provides that PTE is calculated from ‘the original expiration date of the patent, which shall include any patent term adjustment granted under section 154(b).’ PTA extends the nominal 20-year term first. PTE then extends from that adjusted date, subject to the five-year maximum and the 14-year post-approval cap. The practical consequence is that maximizing PTA during prosecution \u2014 by monitoring USPTO response deadlines and minimizing applicant delay \u2014 increases the base to which PTE attaches. A patent with three years of PTA and a five-year PTE results in eight additional years of protection beyond the nominal 20-year term, though the 14-year cap may reduce the effective PTE portion. Companies should model the full stacked calculation for every PTE-eligible patent to identify which patent in the portfolio produces the latest effective expiration date.<\/p>\n\n\n\n

Q: What happens if a company discovers its PTA is understated after the two-month reconsideration window has closed?<\/strong><\/p>\n\n\n\n

The window for requesting reconsideration without fee is two months from patent issue, extendable up to five months with extension fees. If a company misses this window entirely, its administrative remedy is closed, and the only remaining option is a civil action in the Eastern District of Virginia challenging the USPTO’s determination under the APA standard. That standard requires showing the agency’s decision was arbitrary, capricious, an abuse of discretion, or otherwise not in accordance with law \u2014 a demanding burden that requires more than showing the calculation was wrong. The practical takeaway is that post-issuance PTA verification should be a calendar-driven SOP item, not a reactive process triggered by someone noticing something unusual. The September 2024 coding error illustrated that verification should occur across the entire portfolio for any relevant issuance period when a systemic error is identified, not just for individually flagged patents.<\/p>\n\n\n\n

Q: How does the ‘first commercial marketing’ requirement in Section 156 affect companies developing multiple formulations of the same active ingredient?<\/strong><\/p>\n\n\n\n

Section 156 limits PTE to the first commercial marketing of the active ingredient as a drug product. Once the first FDA approval has been granted for a compound and the PTE has been applied, no subsequent approval of the same active ingredient \u2014 whether a new dosage form, a new route of administration, or a new indication \u2014 generates a new PTE opportunity for any patent covering that compound. This is why the first NDA for any active ingredient represents the single PTE eligibility event for that molecule’s patent estate. Companies developing oral formulations of injectables, combination products, or second indications for already-approved active ingredients need to build their IP protection around secondary patents (formulation, method of use, device) and regulatory exclusivities (new clinical investigation, new indication, pediatric) rather than expecting additional PTE. The only exception in the statute is for animal drugs where an approval for food-producing animals follows a non-food-producing animal approval, which can generate a second PTE opportunity under specific conditions.<\/p>\n\n\n\n

Q: What is the strategic difference between challenging a competitor’s PTE calculation in a due diligence petition and challenging the underlying patent validity in Paragraph IV litigation?<\/strong><\/p>\n\n\n\n

These are complementary strategies that generic manufacturers can pursue simultaneously but that produce different outcomes. A successful due diligence petition shortens the PTE period by establishing that the applicant failed to exercise reasonable diligence during some part of the regulatory review period, pulling forward the patent expiration date. This is effective when there is documentary evidence of FDA delays that were caused by the applicant’s failures rather than by normal regulatory processing. Paragraph IV litigation challenges the underlying patent validity or non-infringement, with the potential outcome of invalidating or limiting the patent rather than merely shortening the extension. For generics, the strategic calculus involves considering whether the patent has meaningful invalidity exposure (which drives the Paragraph IV path) versus whether the patent is likely valid but the PTE calculation overstates the recoverable period (which drives the due diligence petition). Some well-funded generics pursue both simultaneously on different legal theories, using the 30-month stay triggered by the Paragraph IV certification to conduct the full discovery process needed for both challenges.<\/p>\n\n\n\n

Q: How should pharmaceutical companies adjust their prosecution strategy in light of the Cellect and Allergan decisions?<\/strong><\/p>\n\n\n\n

The combined reading of Cellect and Allergan creates a prosecution rule: the most commercially critical subject matter \u2014 typically the species-level claims to the actual clinical drug candidate \u2014 should be pursued in the first-filed, first-prosecuted application in the family. That application, once it issues, benefits from the Allergan protection: it cannot be invalidated for ODP by later-filed, later-issued siblings, even if PTA pushes its expiration past those siblings. Continuation applications that claim obvious variations or narrower species can be filed later, and if they generate ODP references under Cellect, the terminal disclaimer mechanism can be used to tie their expiration to the parent \u2014 at the cost of their own PTA accumulation, which is capped by the disclaimer. For companies with large continuation portfolios where some patents received significant PTA without terminal disclaimers, a retroactive portfolio review is warranted to identify patents where the Cellect ODP vulnerability is material. The Allergan first-filed\/first-issued safe harbor will protect some of these, but patents that are not the first-filed application in their family do not benefit from the safe harbor and may still face ODP challenges from earlier-expiring family members.<\/p>\n\n\n\n

\n\n\n\n

References<\/strong><\/h2>\n\n\n\n

[1] Drug Price Competition and Patent Term Restoration Act, Pub. L. No. 98-417, 98 Stat. 1585 (1984). Wikipedia<\/em>. Retrieved April 2026, from https:\/\/en.wikipedia.org\/wiki\/Drug_Price_Competition_and_Patent_Term_Restoration_Act<\/p>\n\n\n\n

[2] Congressional Research Service. (2016). The Hatch-Waxman Act: A Primer<\/em>. EveryCRSReport.com. https:\/\/www.everycrsreport.com\/reports\/R44643.html<\/p>\n\n\n\n

[3] Alacrita Consulting. (n.d.). Pharmaceutical Patent Term Extension: An Overview<\/em>. https:\/\/www.alacrita.com\/whitepapers\/pharmaceutical-patent-term-extension-an-overview<\/p>\n\n\n\n

[4] Azami Global. (2025, September 7). Patent Term Extension (PTE) Under the Hatch-Waxman Act<\/em>. https:\/\/azamiglobal.com\/blog\/patent-term-extension-pte-under-the-hatch-waxman-act\/<\/p>\n\n\n\n

[5] FindLaw. (2017). Patent Term Extensions and Restoration under the Hatch-Waxman Act<\/em>. https:\/\/corporate.findlaw.com\/intellectual-property\/patent-term-extensions-and-restoration-under-the-hatch-waxman-act.html<\/p>\n\n\n\n

[6] Mintz Levin. (2017, June 22). Calculating Patent Term Adjustment: Part 1<\/em>. https:\/\/www.mintz.com\/insights-center\/viewpoints\/2231\/2017-06-calculating-patent-term-adjustment-part-1<\/p>\n\n\n\n

[7] DLA Piper. (2024). Challenging the USPTO’s Patent Term Adjustment calculation: An uphill battle<\/em>. https:\/\/www.dlapiper.com\/en\/insights\/publications\/synthesis\/2024\/challenging-the-usptos-patent-term-adjustment-calculation<\/p>\n\n\n\n

[8] Mondaq. (2024, October 8). USPTO Coding Error Alert: Check Your Patent Term Adjustment (PTA)<\/em>. https:\/\/www.mondaq.com\/unitedstates\/patent\/1527874\/<\/p>\n\n\n\n

[9] Rothwell Figg. (2025, March 19). Federal Circuit: Reissue Patents Get PTE Based on the Original Patent’s Issue Date<\/em>. Biosimilars Law Bulletin<\/em>. https:\/\/www.biosimilarsip.com\/2025\/03\/19\/federal-circuit-reissue-patents-get-pte-based-on-the-original-patents-issue-date\/<\/p>\n\n\n\n

[10] Foley & Lardner. (2025, March 24). Federal Circuit Decision Could Encourage More Reissue Patents<\/em>. https:\/\/www.foley.com\/insights\/publications\/2025\/03\/federal-circuit-decision-could-encourage-more-reissue-patents\/<\/p>\n\n\n\n

[11] Merck Sharp & Dohme B.V. v. Aurobindo Pharma USA, Inc., No. 23-2254 (Fed. Cir. Mar. 13, 2025).<\/p>\n\n\n\n

[12] In re Cellect, LLC, 81 F.4th 1216 (Fed. Cir. 2023), reh’g denied, Jan. 19, 2024, cert. denied, Oct. 7, 2024.<\/p>\n\n\n\n

[13] Allergan USA, Inc. v. MSN Laboratories Private Ltd., 111 F.4th 1358 (Fed. Cir. Aug. 13, 2024).<\/p>\n\n\n\n

[14] Cellect LLC v. Katherine K. Vidal, Director, USPTO, No. 23-1231, cert. denied (U.S. Oct. 7, 2024).<\/p>\n\n\n\n

[15] Venable LLP. (2024, August 27). Navigating Patent Term Adjustment and Double Patenting<\/em>. https:\/\/www.venable.com\/-\/media\/files\/publications\/2024\/08\/navigating-patent-term-adjustment-and-double-paten.pdf<\/p>\n\n\n\n

[16] White & Case. (2024, August 15). Federal Circuit Limits the Application of Obviousness-Type Double Patenting for Patents in the Same Family<\/em>. https:\/\/www.whitecase.com\/insight-alert\/federal-circuit-limits-application-obviousness-type-double-patenting-patents-same<\/p>\n\n\n\n

[17] Jones Day. (2024, October 9). Supreme Court Denies Cellect Petition on Interplay Between PTA and ODP<\/em>. https:\/\/www.jonesday.com\/en\/insights\/2024\/10\/supreme-court-denies-cellect-petition-on-interplay-between-pta-and-odp<\/p>\n\n\n\n

[18] DrugPatentWatch. (2026, February). Patent Term Extension: The Complete PTE Calculation and Regulatory Review Period Playbook<\/em>. https:\/\/www.drugpatentwatch.com\/blog\/calculating-the-regulatory-review-period-for-patent-term-extension\/<\/p>\n\n\n\n

[19] DrugPatentWatch. (2026, February). Patent Term Extension Calculator: Step-by-Step Expert Guide<\/em>. https:\/\/www.drugpatentwatch.com\/blog\/patent-term-extension-calculator-step-by-step-expert-guide\/<\/p>\n\n\n\n

[20] DrugPatentWatch. (2026, March). How Long Does a Drug Patent Actually Last?<\/em> https:\/\/www.drugpatentwatch.com\/blog\/how-long-does-a-drug-patent-last-for-drugs\/<\/p>\n\n\n\n

[21] DrugPatentWatch. (2026, March). Know Your Cliffs: How to Forecast a Drug’s True Market Longevity<\/em>. https:\/\/www.drugpatentwatch.com\/blog\/know-your-cliffs-how-to-forecast-a-drugs-true-market-longevity-using-patent-and-regulatory-exclusivity-data\/<\/p>\n\n\n\n

[22] DrugPatentWatch. (2026, March 22). The $236 Billion Cliff: How Pharma Loses Its Blockbusters and What Replaces Them<\/em>. https:\/\/www.drugpatentwatch.com\/blog\/as-blockbuster-drugs-fizzle-biotech-looks-warily-to-the-next-big-thing\/<\/p>\n\n\n\n

[23] DrugPatentWatch. (2026, March 22). Drug Patent Expiration: The Complete Strategic Guide<\/em>. https:\/\/www.drugpatentwatch.com\/blog\/the-impact-of-drug-patent-expiration-financial-implications-lifecycle-strategies-and-market-dynamics\/<\/p>\n\n\n\n

[24] DrugPatentWatch. (2025, September 11). The Crystal Ball of Pharma: Using Patent Expiry Data to Build a More Accurate 3-Year Drug Spend Forecast<\/em>. https:\/\/www.drugpatentwatch.com\/blog\/the-crystal-ball-of-pharma-using-patent-expiry-data-to-build-a-more-accurate-3-year-drug-spend-forecast\/<\/p>\n\n\n\n

[25] I-MAK. (2025). Overpatented, Overpriced 2025: A Data Brief on Medicare-Negotiated Drugs: Eliquis, Ozempic, Rybelsus and Wegovy<\/em>. https:\/\/www.i-mak.org\/overpatented\/<\/p>\n\n\n\n

[26] DeepCeutix. (2026, February 2). $300 Billion in Pharma Revenue Loses Patent Protection by 2030<\/em>. https:\/\/deepceutix.com\/insights\/patent-cliff-reformulation<\/p>\n\n\n\n

[27] DelveInsight. (2025). The End of Exclusivity: Opportunity or Crisis for Big Players?<\/em> https:\/\/www.delveinsight.com\/blog\/navigating-the-loss-of-exclusivity<\/p>\n\n\n\n

[28] IntuitionLabs. (2026). Drug Patents Expiring in 2026: A Comprehensive Guide<\/em>. https:\/\/intuitionlabs.ai\/articles\/drug-patent-expirations-2026<\/p>\n\n\n\n

[29] Cooley LLP. (2024, August 26). Federal Circuit Limits In re Cellect, Preserving PTA for First-Filed, First-Issued Patents Within a Family<\/em>. https:\/\/www.cooley.com\/news\/insight\/2024\/2024-08-26-federal-circuit-limits-in-re-cellect-preserving-pta-for-first-filed-first-issued-patents-within-a-family<\/p>\n\n\n\n

[30] DLA Piper. (2024, October 17). Effect of patent term extensions on obviousness-type double patenting<\/em>. https:\/\/www.dlapiper.com\/en-us\/insights\/publications\/synthesis\/2024\/effect-of-patent-term-extensions-on-obviousness-double-patenting<\/p>\n\n\n\n

[31] Association for Accessible Medicines. (2024, February 6). Hatch-Waxman Turns 40<\/em>. AAM Press Release. Cited in: Center for Biosimilars. https:\/\/www.centerforbiosimilars.com\/view\/the-hatch-waxman-act-turns-40-the-law-that-made-biosimilars-possible<\/p>\n\n\n\n

[32] Yale Law & Policy Review. (n.d.). Patent Term Extensions and the Last Man Standing<\/em>. https:\/\/yalelawandpolicy.org\/patent-term-extensions-and-last-man-standing<\/p>\n\n\n\n

[33] Mondaq. (2025, April 4). The Interplay of Patent Term Extension (PTE) and Reissue: Merck v. Aurobindo and Its Implications, Part I<\/em>. https:\/\/www.mondaq.com\/unitedstates\/patent\/1773420\/<\/p>\n","protected":false},"excerpt":{"rendered":"

Every pharmaceutical patent starts its life with a 20-year timer running from the filing date. By the time a new […]<\/p>\n","protected":false},"author":1,"featured_media":38496,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"","_lmt_disable":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[10],"tags":[],"class_list":["post-38489","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-insights"],"modified_by":"DrugPatentWatch","_links":{"self":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/38489","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/comments?post=38489"}],"version-history":[{"count":1,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/38489\/revisions"}],"predecessor-version":[{"id":38497,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/38489\/revisions\/38497"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media\/38496"}],"wp:attachment":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media?parent=38489"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/categories?post=38489"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/tags?post=38489"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}